Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 9/20 | 0.65 |
| ▸ | DHFR | P00374 | 1/20 | 0.65 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.65 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.65 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.65 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.65 |
| ▸ | SLC46A1 | Q96NT5 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22104584 | 0.91 | TYMS (0.67) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL7439 | 0.91 | TYMS (0.78) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL16766843 | 0.91 | TYMS (0.78) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL29454789 | 0.91 | TYMS (0.78) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| SCHEMBL3274944 | 0.90 | TYMS (0.70) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| SCHEMBL16366393 | 0.89 | TYMS (0.67) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| SCHEMBL16366259 | 0.87 | TYMS (0.65) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL28116774 | 0.87 | TYMS (0.72) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL4954885 | 0.86 | TYMS (0.88) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| SCHEMBL29677618 | 0.83 | TYMS (0.57) | TYMSDHFRFOLR2FOLR1SLC19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | TYMS 1616/4885DHFR 2599/4885FOLR2 295/4885 |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, ASGR1, FCGR3B | TYMS 2995/4885DHFR 4085/4885FOLR2 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.